| Jersey (Channel Islands)(State or other jurisdiction of incorporation or organization)                                                | 98-0601486(I.R.S. Employer Identification No.)                                  |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
|  5 Riverwalk, Citywest Business Campus, Dublin24, Republic of Ireland (Address of principal executive offices and zip code) |  +353 1 429 7700(Registrant’s telephone number, including area code) |

----

----

|                                                                                                                             |                                                                                        | Page   |
|----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|--------|
|                                                                                                                             |                                                                                        |   |
| PART I                                                                                                                           | FINANCIAL INFORMATION                                                                       |   |
|                                                                                                                             |                                                                                        |   |
| ITEM 1.                                                                                                                          | FINANCIAL STATEMENTS                                                                        |   |
|                                                                                                                             |                                                                                        |   |
| Unaudited Consolidated Balance Sheets at June 30, 2010 and December 31, 2009                                                     | 4                                                                                           |
|                                                                                                                             |                                                                                        |   |
| Unaudited Consolidated Statements of Income for the three months and six months to June 30, 2010 and June 30, 2009               | 6                                                                                           |
|                                                                                                                             |                                                                                        |   |
| Unaudited Consolidated Statement of Changes in Equity for the six months to June 30, 2010                                        | 8                                                                                           |
|                                                                                                                             |                                                                                        |   |
| Unaudited Consolidated Statements of Comprehensive Income for the three months and six months to June 30, 2010 and June 30, 2009 | 9                                                                                           |
|                                                                                                                             |                                                                                        |   |
| Unaudited Consolidated Statements of Cash Flows for the six months to June 30, 2010 and June 30, 2009                            | 10                                                                                          |
|                                                                                                                             |                                                                                        |   |
| Notes to the Unaudited Consolidated Financial Statements                                                                         | 12                                                                                          |
|                                                                                                                             |                                                                                        |   |
| ITEM 2.                                                                                                                          | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 32     |
|                                                                                                                             |                                                                                        |   |
| ITEM 3.                                                                                                                          | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                                  | 49     |
|                                                                                                                             |                                                                                        |   |
| ITEM 4.                                                                                                                          | CONTROLS AND PROCEDURES                                                                     | 49     |
|                                                                                                                             |                                                                                        |   |
| PART II                                                                                                                          | OTHER INFORMATION                                                                           | 49     |
|                                                                                                                             |                                                                                        |   |
| ITEM 1.                                                                                                                          | LEGAL PROCEEDINGS                                                                           | 49     |
|                                                                                                                             |                                                                                        |   |
| ITEM 1A.                                                                                                                         | RISK FACTORS                                                                                | 49     |
|                                                                                                                             |                                                                                        |   |
| ITEM 2.                                                                                                                          | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS                                 | 49     |
|                                                                                                                             |                                                                                        |   |
| ITEM 3.                                                                                                                          | DEFAULTS UPON SENIOR SECURITIES                                                             | 49     |
|                                                                                                                             |                                                                                        |   |
| ITEM 4.                                                                                                                          | OTHER INFORMATION                                                                           | 49     |
|                                                                                                                             |                                                                                        |   |
| ITEM 5.                                                                                                                          | EXHIBITS                                                                                    | 50     |

----

|                                      |   |   |   |   | June 30, |      |    | December 31, |   |
|-------------------------------------------|--------|--------|--------|--------|----------|-----------|---------|--------------|--------|
|                                      |   |   |   |   | 2010     |      |    | 2009         |   |
|                                      |   | Notes  |   |   |     | $’M |    |         |   | $’M |   |
| ASSETS                                    |   |   |   |   |     |      |    |         |   |   |   |
| Current assets:                           |   |   |   |   |     |      |    |         |   |   |   |
| Cash and cash equivalents                 |   |   |   |   |     | 682.5     |    |         |   | 498.9 |   |
| Restricted cash                           |   |   |   |   |     | 27.1      |    |         |   | 33.1 |   |
| Accounts receivable, net                  |   |   | 4      |   |     |      | 612.5   |         |   |   | 597.5 |   |
| Inventories                               |   |   | 5      |   |     |      | 232.7   |         |   |   | 189.7 |   |
| Deferred tax asset                        |   |   |   |   |     |      | 140.0   |         |   |   | 135.8 |   |
| Prepaid expenses and other current assets |   |   | 6      |   |     |      | 195.1   |         |   |   | 115.2 |   |
| Total current assets                      |   |   |   |   |     |      | 1,889.9 |         |   |   | 1,570.2 |   |
|                                      |   |   |   |   |     |      |    |         |   |   |   |   |
| Non-current assets:                       |   |   |   |   |     |      |    |         |   |   |   |   |
| Investments                               |   |   | 7      |   |     |      | 84.0    |         |   |   | 105.7 |   |
| Property, plant and equipment, net        |   |   | 8      |   |     |      | 801.1   |         |   |   | 676.8 |   |
| Goodwill                                  |   |   |   |   |     |      | 355.7   |         |   |   | 384.7 |   |
| Other intangible assets, net              |   |   | 9      |   |     |      | 1,653.1 |         |   |   | 1,790.7 |   |
| Deferred tax asset                        |   |   |   |   |     |      | 76.4    |         |   |   | 79.0 |   |
| Other non-current assets                  |   |   |   |   |     |      | 8.7     |         |   |   | 10.4 |   |
| Total assets                              |   |   |   |   |     |      | 4,868.9 |         |   |   | 4,617.5 |   |
|                                      |   |   |   |   |     |      |    |         |   |   |   |   |
| LIABILITIES AND EQUITY                    |   |   |   |   |     |      |    |         |   |   |   |   |
| Current liabilities:                      |   |   |   |   |     |      |    |         |   |   |   |   |
| Accounts payable and accrued expenses     |   |   | 10     |   |     |      | 1,031.9 |         |   |   | 929.1 |   |
| Deferred tax liability                    |   |   |   |   |     |      | 2.9     |         |   |   | 2.9 |   |
| Other current liabilities                 |   |   | 11     |   |     |      | 41.1    |         |   |   | 88.0 |   |
| Total current liabilities                 |   |   |   |   |     |      | 1,075.9 |         |   |   | 1,020.0 |   |
|                                      |   |   |   |   |     |      |    |         |   |   |   |   |
| Non-current liabilities                   |   |   |   |   |     |      |    |         |   |   |   |   |
| Convertible bonds                         |   |   |   |   |     |      | 1,100.0 |         |   |   | 1,100.0 |   |
| Other long-term debt                      |   |   | 12     |   |     |      | 6.8     |         |   |   | 43.6 |   |
| Deferred tax liability                    |   |   |   |   |     |      | 341.8   |         |   |   | 294.3 |   |
| Other non-current liabilities             |   |   | 13     |   |     |      | 226.0   |         |   |   | 247.1 |   |
| Total liabilities                         |   |   |   |   |     |      | 2,750.5 |         |   |   | 2,705.0 |   |
| Commitments and contingencies             |   |   | 14     |   |     |      |    |         |   |   |   |   |

----

|                                                                                                                                                                                                    |   |   |   |   |      |    |   |         |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|-----------|---------|--------|--------------|-----------|
|                                                                                                                                                                                                    |   |   |   |   | June 30,  |    |   | December 31, |      |
|                                                                                                                                                                                                    |   |   |   |   | 2010      |    |   | 2009         |      |
|                                                                                                                                                                                                    |   | Notes  |   |   | $’M |    |   |         | $’M |   |
|                                                                                                                                                                                                    |   |   |   |   |      |    |   |         |      |   |   |
| Equity:                                                                                                                                                                                                 |   |   |   |   |      |    |   |         |      |   |   |
| Common stock of 5p par value; 1,000 million shares authorized; and 562.1 million shares issued and outstanding (2009: 1,000 million shares authorized; and 561.5 million shares issued and outstanding) |   |   |   |   |      | 55.7    |   |         |      | 55.6 |   |
| Additional paid-in capital                                                                                                                                                                              |   |   |   |   |      | 2,711.8 |   |         |      | 2,677.6 |   |
| Treasury stock: 15.4 million shares (2009: 17.8 million shares)                                                                                                                                         |   |   |   |   |      | (308.9  | )      |         |      | (347.4 | ) |
| Accumulated other comprehensive income                                                                                                                                                                  |   |   |   |   |      | 45.8    |   |         |      | 149.1 |   |
| Accumulated deficit                                                                                                                                                                                     |   |   |   |   |      | (386.0  | )      |         |      | (622.4 | ) |
| Total equity                                                                                                                                                                                            |   |   |   |   |      | 2,118.4 |   |         |      | 1,912.5 |   |
| Total liabilities and equity                                                                                                                                                                            |   |   |   |   |      | 4,868.9 |   |         |      | 4,617.5 |   |

----

|                                                                                                    |   |   |   |   | 3 months to   |      |   | 3 months to   |   |      | 6 months to   |   |   | 6 months to   |    |
|---------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|---------------|-----------|--------|---------------|--------|-----------|---------------|--------|--------|---------------|---------|
|                                                                                                    |   |   |   |   | June 30, 2010 |      |   | June 30, 2009 |   |      | June 30, 2010 |   |   | June 30, 2009 |    |
|                                                                                                    |   | Notes  |   |   |          | $’M |   |          |   | $’M |          |   |   | $’M     |    |   |   | $’M |   |
| Revenues:                                                                                               |   |   |   |   |          |      |   |          |   |      |          |   |   |          |    |   |   |   |   |
|   Product sales                                                                               |   |   |   |   |          | 764.3     |   |          |   | 558.4     |          |   |   | 1,482.4       |    |   |   | 1,314.3 |   |
|   Royalties                                                                                   |   |   |   |   |          | 82.7      |   |          |   | 66.9      |          |   |   | 178.0         |    |   |   | 117.5 |   |
|   Other revenues                                                                              |   |   |   |   |          | 2.4       |   |          |   | 4.4       |          |   |   | 5.1           |    |   |   | 15.6 |   |
| Total revenues                                                                                          |   |   |   |   |          | 849.4     |   |          |   | 629.7     |          |   |   | 1,665.5       |    |   |   | 1,447.4 |   |
| Costs and expenses:                                                                                     |   |   |   |   |          |      |   |          |   |      |          |   |   |          |    |   |   |   |   |
|   Cost of product sales (1)                                                                   |   |   |   |   |          | 119.1     |   |          |   | 96.4      |          |   |   | 221.0         |    |   |   | 180.0 |   |
|   Research and development                                                                    |   |   |   |   |          | 147.0     |   |          |   | 158.7     |          |   |   | 278.0         |    |   |   | 344.6 |   |
|   Selling, general and administrative (1)                                                     |   |   |   |   |          | 354.4     |   |          |   | 334.7     |          |   |   | 714.3         |    |   |   | 653.3 |   |
|   Gain on sale of product rights                                                              |   |   |   |   |          | (4.1      | )      |          |   | -         |          |   |   | (4.1          | )       |   |   | - |   |
|   Reorganization costs                                                                        |   |   | 3      |   |          |      | 8.6    |          |   |      | 2.9           |   |   |          | 13.6    |   |   |   | 5.1 |   |
|   Integration and acquisition costs                                                           |   |   |   |   |          |      | -      |          |   |      | 2.3           |   |   |          | 0.6     |   |   |   | 3.8 |   |
| Total operating expenses                                                                                |   |   |   |   |          |      | 625.0  |          |   |      | 595.0         |   |   |          | 1,223.4 |   |   |   | 1,186.8 |   |
|                                                                                                    |   |   |   |   |          |      |   |          |   |      |          |   |   |          |    |   |   |   |   |   |
| Operating income                                                                                        |   |   |   |   |          |      | 224.4  |          |   |      | 34.7          |   |   |          | 442.1   |   |   |   | 260.6 |   |
| Interest income                                                                                         |   |   |   |   |          |      | 0.5    |          |   |      | 0.6           |   |   |          | 0.8     |   |   |   | 1.3 |   |
| Interest expense                                                                                        |   |   |   |   |          |      | (8.3   | )             |   |      | (10.1         | )      |   |          | (17.3   | ) |   |   | (21.2 | ) |
| Other (expenses)/income, net                                                                            |   |   |   |   |          |      | (2.6   | )             |   |      | 4.7           |   |   |          | 8.2     |   |   |   | 54.9 |   |
| Total other (expenses)/income, net                                                                      |   |   |   |   |          |      | (10.4  | )             |   |      | (4.8          | )      |   |          | (8.3    | ) |   |   | 35.0 |   |
| Income from continuing operations before income taxes and equity in earnings of equity method investees |   |   |   |   |          |      | 214.0  |          |   |      | 29.9          |   |   |          | 433.8   |   |   |   | 295.6 |   |
| Income taxes                                                                                            |   |   |   |   |          |      | (54.5  | )             |   |      | 23.4          |   |   |          | (108.1  | ) |   |   | (26.1 | ) |
| Equity in earnings of equity method investees, net of taxes                                             |   |   |   |   |          |      | 1.0    |          |   |      | 0.5           |   |   |          | 0.5     |   |   |   | 0.4 |   |
| Income from continuing operations, net of taxes                                                         |   |   |   |   |          |      | 160.5  |          |   |      | 53.8          |   |   |          | 326.2   |   |   |   | 269.9 |   |
|                                                                                                    |   |   |   |   |          |      |   |          |   |      |          |   |   |          |    |   |   |   |   |   |
| Loss from discontinued operations (net of income tax expense of $nil in all periods)                    |   |   |   |   |          |      | -      |          |   |      | (9.8          | )      |   |          | -       |   |   |   | (12.4 | ) |
| Net income                                                                                              |   |   |   |   |          |      | 160.5  |          |   |      | 44.0          |   |   |          | 326.2   |   |   |   | 257.5 |   |
|                                                                                                    |   |   |   |   |          |      |   |          |   |      |          |   |   |          |    |   |   |   |   |   |
| Add: Net loss attributable to the noncontrolling interest in subsidiaries                               |   |   |   |   |          |      | -      |          |   |      | 0.1           |   |   |          | -       |   |   |   | 0.2 |   |
| Net income attributable to Shire plc                                                                    |   |   |   |   |          |      | 160.5  |          |   |      | 44.1          |   |   |          | 326.2   |   |   |   | 257.7 |   |

| (1) | Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.4 million for three months to June 30, 2010 (2009: $0.4 million) and $0.9 million for the six months to June 30, 2010 (2009: $0.9 million). Selling, general and administrative costs includes amortization of intangible assets relating to intellectual property rights acquired of $33.8 million for the three months to June 30, 2010 (2009: $34.3 million) and $68.4 million for the six months to June 30, 2010 (2009: $66.8 million). |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                                         |   |   | 3 months to   |   |   | 3 months to   |   |   | 6 months to   |   |   | 6 months to   |   |
|------------------------------------------------------------------------------|--------|--------|---------------|--------|--------|---------------|--------|--------|---------------|--------|--------|---------------|--------|
|                                                                         | Notes  |   | June 30, 2010 |   |   | June 30, 2009 |   |   | June 30, 2010 |   |   | June 30, 2009 |   |
| Earning per ordinary share - basic                                           |   |   |          |   |   |          |   |   |          |   |   |          |   |
|                                                                         |   |   |          |   |   |          |   |   |          |   |   |          |   |
| Earnings from continuing operations attributable to Shire plc shareholders   |   |   |          | 29.4   | c      |          |   | 10.0   | c             |   |   | 59.8          | c      |   |   | 50.0 | c |
|                                                                         |   |   |          |   |   |          |   |   |          |   |   |          |   |   |   |   |   |
| Loss from discontinued operations attributable to Shire plc shareholders     |   |   |          | -      |   |          |   | (1.8c  | )             |   |   | -             |   |   |   | (2.3c | ) |
|                                                                         |   |   |          |   |   |          |   |   |          |   |   |          |   |   |   |   |   |
| Earnings per ordinary share attributable to Shire plc shareholders - basic   |   |   |          | 29.4   | c      |          |   | 8.2    | c             |   |   | 59.8          | c      |   |   | 47.7 | c |
|                                                                         |   |   |          |   |   |          |   |   |          |   |   |          |   |   |   |   |   |
| Earnings per ordinary share - diluted                                        |   |   |          |   |   |          |   |   |          |   |   |          |   |   |   |   |   |
|                                                                         |   |   |          |   |   |          |   |   |          |   |   |          |   |   |   |   |   |
| Earnings from continuing operations attributable to Shire plc shareholders   |   |   |          | 28.6   | c      |          |   | 9.9    | c             |   |   | 58.2          | c      |   |   | 49.6 | c |
|                                                                         |   |   |          |   |   |          |   |   |          |   |   |          |   |   |   |   |   |
| Loss from discontinued operations attributable to Shire plc shareholders     |   |   |          | -      |   |          |   | (1.8c  | )             |   |   | -             |   |   |   | (2.3c | ) |
| Earnings per ordinary share attributable to Shire plc shareholders - diluted |   |   |          | 28.6   | c      |          |   | 8.1    | c             |   |   | 58.2          | c      |   |   | 47.3 | c |
|                                                                         |   |   |          |   |   |          |   |   |          |   |   |          |   |   |   |   |   |
| Weighted average number of shares (millions):                                |   |   |          |   |   |          |   |   |          |   |   |          |   |   |   |   |   |
| Basic                                                                        | 17     |   |          | 546.6  |   |          |   | 539.9  |          |   |   | 545.7         |   |   |   | 539.7 |   |
| Diluted                                                                      | 17     |   |          | 590.0  |   |          |   | 543.4  |          |   |   | 589.1         |   |   |   | 545.0 |   |

|                                            |   | 3 months to   |      |   | 3 months to   |   |      | 6 months to   |   |   | 6 months to   |   |
|-------------------------------------------------|--------|---------------|-----------|--------|---------------|--------|-----------|---------------|--------|--------|---------------|--------|
|                                            |   | June 30, 2010 |      |   | June 30, 2009 |   |      | June 30, 2010 |   |   | June 30, 2009 |   |
|                                            |   |          | $’M |   |          |   | $’M |          |   |   | $’M     |   |   |   | $’M |   |
| Amounts attributable to Shire plc               |   |          |      |   |          |   |      |          |   |   |          |   |   |   |   |   |
|                                            |   |          |      |   |          |   |      |          |   |   |          |   |   |   |   |   |
| Income from continuing operations, net of taxes |   |          | 160.5     |   |          |   | 53.9      |          |   |   | 326.2         |   |   |   | 270.1 |   |
| Loss from discontinued operations, net of taxes |   |          | -         |   |          |   | (9.8      | )             |   |   | -             |   |   |   | (12.4 | ) |
| Net income attributable to Shire plc            |   |          | 160.5     |   |          |   | 44.1      |          |   |   | 326.2         |   |   |   | 257.7 |   |

----

|                                                                           |   | Shire plc shareholders equity |   |   |                            |   |
|--------------------------------------------------------------------------------|--------|-------------------------------|--------|--------|---------------------------------|--------|
|                                                                           |   | Common stock$'M               |   |   | Common stockNumber of sharesM's |   |   | Additional paid-in capital$’M |   |   | Treasury stock$'M |   |   | Accumulated other comprehensive income$'M |   |   | Accumulated deficit$'M |   |   | Total equity$'M |   |
| As at January 1, 2010                                                          |   |                          | 55.6   |   |                            |   | 561.5 |   |   |   | 2,677.6 |   |   |   | (347.4 | ) |   |   | 149.1 |   |   |   | (622.4 | ) |   |   | 1,912.5 |   |
| Net income                                                                     |   |                          | -      |   |                            |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 326.2 |   |   |   | 326.2 |   |
| Foreign currency translation                                                   |   |                          | -      |   |                            |   | - |   |   |   | - |   |   |   | - |   |   |   | (82.2 | ) |   |   | - |   |   |   | (82.2 | ) |
| Options exercised                                                              |   |                          | 0.1    |   |                            |   | 0.6 |   |   |   | 1.5 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 1.6 |   |
| Share-based compensation                                                       |   |                          | -      |   |                            |   | - |   |   |   | 28.3 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 28.3 |   |
|                                                                           |   |                          |   |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Excess tax benefit associated with exercise of stock options                   |   |                          | -      |   |                            |   | - |   |   |   | 4.4 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 4.4 |   |
|                                                                           |   |                          |   |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shares purchased by the Employee Share Ownership Trust ("ESOT")                |   |                          | -      |   |                            |   | - |   |   |   | - |   |   |   | (1.7 | ) |   |   | - |   |   |   | - |   |   |   | (1.7 | ) |
|                                                                           |   |                          |   |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shares released by ESOT to satisfy exercise of stock options                   |   |                          | -      |   |                            |   | - |   |   |   | - |   |   |   | 40.2 |   |   |   | - |   |   |   | (40.0 | ) |   |   | 0.2 |   |
|                                                                           |   |                          |   |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Unrealized holding loss on available-for-sale securities, net of taxes         |   |                          | -      |   |                            |   | - |   |   |   | - |   |   |   | - |   |   |   | (22.6 | ) |   |   | - |   |   |   | (22.6 | ) |
|                                                                           |   |                          |   |   |                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other than temporary impairment of available-for-sale securities, net of taxes |   |                          | -      |   |                            |   | - |   |   |   | - |   |   |   | - |   |   |   | 1.5 |   |   |   | - |   |   |   | 1.5 |   |
| Dividends                                                                      |   |                          | -      |   |                            |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (49.8 | ) |   |   | (49.8 | ) |
| As at June 30, 2010                                                            |   |                          | 55.7   |   |                            |   | 562.1 |   |   |   | 2,711.8 |   |   |   | (308.9 | ) |   |   | 45.8 |   |   |   | (386.0 | ) |   |   | 2,118.4 |   |

----

|                                                                                                                        |   | 3 months to |   |   | 3 months to |   |   | 6 months to |   |   | 6 months to |   |
|-----------------------------------------------------------------------------------------------------------------------------|--------|-------------|--------|--------|-------------|--------|--------|-------------|--------|--------|-------------|--------|
|                                                                                                                        |   | June 30,    |   |   | June 30,    |   |   | June 30,    |   |   | June 30,    |   |
|                                                                                                                        |   | 2010        |   |   | 2009        |   |   | 2010        |   |   | 2009        |   |
|                                                                                                                        |   | $'M         |   |   | $'M         |   |   | $'M         |   |   | $'M         |   |
|                                                                                                                        |   |        |   |   |        |   |   |        |   |   |        |   |
| Net income                                                                                                                  |   |        | 160.5  |   |        |   | 44.0   |        |   |   | 326.2       |   |   |   | 257.5 |   |
| Other comprehensive income:                                                                                                 |   |        |   |   |        |   |   |        |   |   |        |   |   |   |   |   |
| Foreign currency translation adjustments                                                                                    |   |        | (47.1  | )      |        |   | (2.4   | )           |   |   | (82.2       | )      |   |   | 11.4 |   |
| Unrealized holding (loss)/gain on available-for-sale securities (net of taxes of $1.6 million, $nil, $2.6 million and $nil) |   |        | (15.9  | )      |        |   | 10.7   |        |   |   | (22.6       | )      |   |   | 11.3 |   |
| Other than temporary impairment of available-for-sale securities (net of taxes of $nil, $nil, $nil and $nil)                |   |        | 1.5    |   |        |   | -      |        |   |   | 1.5         |   |   |   | - |   |
| Comprehensive income                                                                                                        |   |        | 99.0   |   |        |   | 52.3   |        |   |   | 222.9       |   |   |   | 280.2 |   |
| Add: net loss attributable to the noncontrolling interest in subsidiaries                                                   |   |        | -      |   |        |   | 0.1    |        |   |   | -           |   |   |   | 0.2 |   |
| Comprehensive income attributable to Shire plc                                                                              |   |        | 99.0   |   |        |   | 52.4   |        |   |   | 222.9       |   |   |   | 280.4 |   |

|                                                                          |   | June 30, |      |   | December 31, |   |
|-------------------------------------------------------------------------------|--------|----------|-----------|--------|--------------|--------|
|                                                                          |   | 2010     |      |   | 2009         |   |
|                                                                          |   |     | $’M |   |         |   | $’M |   |
| Foreign currency translation adjustments                                      |   |     | 54.5      |   |         |   | 136.7 |   |
| Unrealized holding (loss)/gain on available-for-sale securities, net of taxes |   |     | (8.7      | )      |         |   | 12.4 |   |
| Accumulated other comprehensive income                                        |   |     | 45.8      |   |         |   | 149.1 |   |

----

|                                                                               |   | 6 months to |      |   | 6 months to |   |
|------------------------------------------------------------------------------------|--------|-------------|-----------|--------|-------------|--------|
|                                                                               |   | June 30,    |      |   | June 30,    |   |
|                                                                               |   | 2010        |      |   | 2009        |   |
|                                                                               |   |        | $’M |   |        |   | $’M |   |
| CASH FLOWS FROM OPERATING ACTIVITIES:                                              |   |        |      |   |        |   |   |   |
| Net income                                                                         |   |        | 326.2     |   |        |   | 257.5 |   |
| Adjustments to reconcile net income to net cash provided by operating activities:  |   |        |      |   |        |   |   |   |
| Loss from discontinued operations                                                  |   |        | -         |   |        |   | 12.4 |   |
| Depreciation and amortization                                                      |   |        | 129.1     |   |        |   | 117.7 |   |
| Share based compensation                                                           |   |        | 26.7      |   |        |   | 33.2 |   |
| Gain on sale of non-current investments                                            |   |        | (11.1     | )      |        |   | (55.2 | ) |
| Gain on sale of product rights                                                     |   |        | (4.1      | )      |        |   | - |   |
| Other                                                                              |   |        | 11.0      |   |        |   | 6.3 |   |
| Movement in deferred taxes                                                         |   |        | 58.8      |   |        |   | (45.7 | ) |
| Equity in earnings of equity method investees                                      |   |        | (0.5      | )      |        |   | (0.4 | ) |
|                                                                               |   |        |      |   |        |   |   |   |
| Changes in operating assets and liabilities:                                       |   |        |      |   |        |   |   |   |
| Increase in accounts receivable                                                    |   |        | (43.9     | )      |        |   | (42.9 | ) |
| Increase in sales deduction accrual                                                |   |        | 154.3     |   |        |   | 117.5 |   |
| Increase in inventory                                                              |   |        | (50.1     | )      |        |   | (12.8 | ) |
| Increase in prepayments and other current assets                                   |   |        | (82.5     | )      |        |   | (33.8 | ) |
| (Increase)/decrease in other assets                                                |   |        | (0.8      | )      |        |   | 4.4 |   |
| Decrease in accounts and notes payable and other liabilities                       |   |        | (43.2     | )      |        |   | (101.2 | ) |
| Returns on investment from joint venture                                           |   |        | -         |   |        |   | 4.9 |   |
| Cash flows used in discontinued operations                                         |   |        | -         |   |        |   | (5.9 | ) |
| Net cash provided by operating activities (A)                                      |   |        | 469.9     |   |        |   | 256.0 |   |
|                                                                               |   |        |      |   |        |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                               |   |        |      |   |        |   |   |   |
| Movements in restricted cash                                                       |   |        | 6.0       |   |        |   | (6.6 | ) |
| Purchases of subsidiary undertakings and businesses, net of cash acquired          |   |        | -         |   |        |   | (75.5 | ) |
| Purchases of property, plant and equipment                                         |   |        | (208.1    | )      |        |   | (101.8 | ) |
| Purchases of intangible assets                                                     |   |        | (2.7      | )      |        |   | (6.0 | ) |
| Proceeds from disposal of non-current investments and property plant and equipment |   |        | 2.1       |   |        |   | 19.6 |   |
| Proceeds from disposal of subsidiary undertakings                                  |   |        | -         |   |        |   | 6.7 |   |
| Returns from equity investments                                                    |   |        | -         |   |        |   | 0.2 |   |
| Net cash used in investing activities (B)                                          |   |        | (202.7    | )      |        |   | (163.4 | ) |

----

|                                                |   | 6 months to |      |   | 6 months to |   |
|-----------------------------------------------------|--------|-------------|-----------|--------|-------------|--------|
|                                                |   | June 30,    |      |   | June 30,    |   |
|                                                |   | 2010        |      |   | 2009        |   |
|                                                |   |        | $’M |   |        |   | $’M |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:               |   |        |      |   |        |   |   |   |
| Payment under building financing obligation         |   |        | (1.3      | )      |        |   | (3.0 | ) |
| Extinguishment of building finance obligation       |   |        | (43.1     | )      |        |   | - |   |
| Tax benefit of stock based compensation             |   |        | 4.4       |   |        |   | - |   |
| Proceeds from exercise of options                   |   |        | 1.8       |   |        |   | 1.0 |   |
| Payment of dividend                                 |   |        | (49.8     | )      |        |   | (43.0 | ) |
| Payments to acquire shares by ESOT                  |   |        | (1.7      | )      |        |   | (1.0 | ) |
| Net cash used in financing activities(C)            |   |        | (89.7     | )      |        |   | (46.0 | ) |
| Effect of foreign exchange rate changes on cash     |   |        |      |   |        |   |   |   |
| and cash equivalents (D)                            |   |        | 6.1       |   |        |   | (1.5 | ) |
| Net increase in cash and cash equivalents (A+B+C+D) |   |        | 183.6     |   |        |   | 45.1 |   |
| Cash and cash equivalents at beginning of period    |   |        | 498.9     |   |        |   | 218.2 |   |
| Cash and cash equivalents at end of period          |   |        | 682.5     |   |        |   | 263.3 |   |

| Supplemental information associated with continuing                                                                                |   |        |      |   |        |   |
|------------------------------------------------------------------------------------------------------------------------------------|--------|-------------|-----------|--------|-------------|--------|
| operations:                                                                                                                        |   |        |      |   |        |   |
|                                                                                                                               |   |        |      |   |        |   |
|                                                                                                                               |   | 6 months to |      |   | 6 months to |   |
|                                                                                                                               |   | June 30,    |      |   | June 30,    |   |
|                                                                                                                               |   | 2010        |      |   | 2009        |   |
|                                                                                                                               |   |        | $’M |   |        |   | $’M |   |
|                                                                                                                               |   |        |      |   |        |   |   |   |
| Interest paid                                                                                                                      |   |        | (13.0     | )      |        |   | (17.6 | ) |
| Income taxes paid                                                                                                                  |   |        | (205.0    | )      |        |   | (119.2 | ) |
|                                                                                                                               |   |        |      |   |        |   |   |   |
| Non cash investing and financing activities:                                                                                       |   |        |      |   |        |   |   |   |
| Equity in Vertex Pharmaceuticals, Inc. (“Vertex”) received as part consideration for disposal ofnon-current investment |   |        | 9.1       |   |        |   | 50.8 |   |
| Building financing obligation                                                                                                      |   |        | -         |   |        |   | 7.1 |   |

----

----

----

----

|                             |   | Opening liability |   |   | Amount         |   |   |          |   |   | Closing       |   |
|----------------------------------|--------|-------------------|--------|--------|----------------|--------|--------|---------------|--------|--------|---------------|--------|
|                             |   | at January 1,     |   |   | charged to re- |   |   |          |   |   | liability at  |   |
|                             |   | 2010              |   |   | organization   |   |   | Paid/Utilized |   |   | June 30, 2010 |   |
|                             |   | $'M               |   |   | $'M            |   |   | $'M           |   |   | $'M           |   |
|                             |   |              |   |   |           |   |   |          |   |   |          |   |
| Involuntary termination benefits |   |              | 4.1    |   |           |   | 6.2    |          |   |   | (2.4          | )      |   |   | 7.9 |   |
| Contract termination costs       |   |              | 2.8    |   |           |   | -      |          |   |   | (2.8          | )      |   |   | - |   |
| Other termination costs          |   |              | -      |   |           |   | 7.4    |          |   |   | (2.6          | )      |   |   | 4.8 |   |
|                             |   |              | 6.9    |   |           |   | 13.6   |          |   |   | (7.8          | )      |   |   | 12.7 |   |

|                            |   | 2010   |      |   | 2009   |   |
|---------------------------------|--------|--------|-----------|--------|--------|--------|
|                            |   |   | $’M |   |   |   | $’M |   |
| As at January 1,                |   |   | 20.8      |   |   |   | 20.2 |   |
| Provision charged to operations |   |   | 85.2      |   |   |   | 54.1 |   |
| Provision utilization           |   |   | (83.2     | )      |   |   | (61.4 | ) |
| As at June 30,                  |   |   | 22.8      |   |   |   | 12.9 |   |

|             |   | June 30, |      |   | December 31, |   |
|------------------|--------|----------|-----------|--------|--------------|--------|
|             |   | 2010     |      |   | 2009         |   |
|             |   |     | $’M |   |         |   | $’M |   |
| Finished goods   |   |     | 66.6      |   |         |   | 50.9 |   |
| Work-in-progress |   |     | 118.4     |   |         |   | 102.1 |   |
| Raw materials    |   |     | 47.7      |   |         |   | 36.7 |   |
|             |   |     | 232.7     |   |         |   | 189.7 |   |

----

|                         |   | June 30, |      |   | December 31, |   |
|------------------------------|--------|----------|-----------|--------|--------------|--------|
|                         |   | 2010     |      |   | 2009         |   |
|                         |   |     | $’M |   |         |   | $’M |   |
| Prepaid expenses             |   |     | 37.8      |   |         |   | 44.9 |   |
| Income tax receivable        |   |     | 112.1     |   |         |   | - |   |
| Value added taxes receivable |   |     | 15.4      |   |         |   | 37.3 |   |
| Other current assets         |   |     | 29.8      |   |         |   | 33.0 |   |
|                         |   |     | 195.1     |   |         |   | 115.2 |   |

|                                              |   | June 30, |      |   | December 31, |   |
|---------------------------------------------------|--------|----------|-----------|--------|--------------|--------|
|                                              |   | 2010     |      |   | 2009         |   |
|                                              |   |     | $’M |   |         |   | $’M |   |
| Land and buildings                                |   |     | 519.2     |   |         |   | 398.7 |   |
| Office furniture, fittings and equipment          |   |     | 289.9     |   |         |   | 280.5 |   |
| Warehouse, laboratory and manufacturing equipment |   |     | 111.7     |   |         |   | 114.5 |   |
| Assets under construction                         |   |     | 242.5     |   |         |   | 193.2 |   |
|                                              |   |     | 1,163.3   |   |         |   | 986.9 |   |
| Less: Accumulated depreciation                    |   |     | (362.2    | )      |         |   | (310.1 | ) |
|                                              |   |     | 801.1     |   |         |   | 676.8 |   |

----

|                                  |   | June 30, |      |   | December 31, |   |
|---------------------------------------|--------|----------|-----------|--------|--------------|--------|
|                                  |   | 2010     |      |   | 2009         |   |
|                                  |   |     | $’M |   |         |   | $’M |   |
| Intellectual property rights acquired |   |     |      |   |         |   |   |   |
| Currently marketed products           |   |     | 2,272.6   |   |         |   | 2,351.6 |   |
| IPR&D                             |   |     | 6.1       |   |         |   | 6.1 |   |
| Favorable manufacturing contracts     |   |     | 8.7       |   |         |   | 8.7 |   |
|                                  |   |     | 2,287.4   |   |         |   | 2,366.4 |   |
|                                  |   |     |      |   |         |   |   |   |
| Less: Accumulated amortization        |   |     | (634.3    | )      |         |   | (575.7 | ) |
|                                  |   |     | 1,653.1   |   |         |   | 1,790.7 |   |

|                         |   | Other intangible |      |
|------------------------------|--------|------------------|-----------|
|                         |   | assets           |      |
|                         |   |             | $’M |   |
|                         |   |             |      |   |
| As at January 1, 2010        |   |             | 1,790.7   |   |
| Acquisitions                 |   |             | 2.7       |   |
| Amortization charged         |   |             | (69.3     | ) |
| Foreign currency translation |   |             | (71.0     | ) |
| As at June 30, 2010          |   |             | 1,653.1   |   |

----

|                                               |   | June 30, |      |   | December 31, |   |
|----------------------------------------------------|--------|----------|-----------|--------|--------------|--------|
|                                               |   | 2010     |      |   | 2009         |   |
|                                               |   |     | $’M |   |         |   | $’M |   |
| Trade accounts payable and accrued purchases       |   |     | 164.7     |   |         |   | 170.6 |   |
| Accrued rebates – Medicaid                   |   |     | 334.2     |   |         |   | 188.2 |   |
| Accrued rebates – Managed care               |   |     | 156.7     |   |         |   | 153.4 |   |
| Sales return reserve                               |   |     | 67.7      |   |         |   | 62.7 |   |
| Accrued bonuses                                    |   |     | 51.6      |   |         |   | 66.8 |   |
| Accrued employee compensation and benefits payable |   |     | 49.3      |   |         |   | 42.6 |   |
| Research and development accruals                  |   |     | 49.7      |   |         |   | 53.1 |   |
| Marketing accruals                                 |   |     | 27.3      |   |         |   | 31.5 |   |
| Deferred revenue                                   |   |     | 16.3      |   |         |   | 52.2 |   |
| Other accrued expenses                             |   |     | 114.4     |   |         |   | 108.0 |   |
|                                               |   |     | 1,031.9   |   |         |   | 929.1 |   |

|                      |   | June 30, |      |   | December 31, |   |
|---------------------------|--------|----------|-----------|--------|--------------|--------|
|                      |   | 2010     |      |   | 2009         |   |
|                      |   |     | $’M |   |         |   | $’M |   |
| Income taxes payable      |   |     | -         |   |         |   | 46.7 |   |
| Value added taxes         |   |     | 11.9      |   |         |   | 10.3 |   |
| Other accrued liabilities |   |     | 29.2      |   |         |   | 31.0 |   |
|                      |   |     | 41.1      |   |         |   | 88.0 |   |

----

|                      |   | June 30, |      |   | December 31, |   |
|---------------------------|--------|----------|-----------|--------|--------------|--------|
|                      |   | 2010     |      |   | 2009         |   |
|                      |   |     | $’M |   |         |   | $’M |   |
| Income taxes payable      |   |     | 166.8     |   |         |   | 170.4 |   |
| Deferred revenue          |   |     | 15.7      |   |         |   | 20.0 |   |
| Deferred rent             |   |     | 13.7      |   |         |   | 14.5 |   |
| Insurance provisions      |   |     | 19.7      |   |         |   | 18.3 |   |
| Other accrued liabilities |   |     | 10.1      |   |         |   | 23.9 |   |
|                      |   |     | 226.0     |   |         |   | 247.1 |   |

|       |   | Operating |      |
|------------|--------|-----------|-----------|
|       |   | leases    |      |
|       |   |      | $’M |   |
| 2010  |   |      | 16.6      |   |
| 2011  |   |      | 30.1      |   |
| 2012  |   |      | 16.8      |   |
| 2013  |   |      | 14.4      |   |
| 2014  |   |      | 13.9      |   |
| 2015  |   |      | 11.7      |   |
| Thereafter |   |      | 17.9      |   |
|       |   |      | 121.4     |   |

----

----

----

----

----

|        |                                      | Fair value |     |      | Fair value |         |
|-------------|-------------------------------------------|------------|----------|-----------|------------|--------------|
|        |                                      |       | June 30, |      |       | December 31, |   |
|        |                                      |       | 2010     |      |       | 2009         |   |
|        |                                      |       |     | $’M |       |         |   | $’M |   |
| Assets      | Prepaid expenses and other current assets |       |     | 2.3       |       |         |   | 5.4 |   |
| Liabilities | Other current liabilities                 |       |     | 5.8       |       |         |   | 1.2 |   |

|                       | Location of net gain/(loss)recognized in income |   | Amount of net gain/(loss) recognized in income |      |
|----------------------------|-------------------------------------------------|--------|------------------------------------------------|-----------|
| Six months to              |                                            |   | June 30,                                       |      |   | June 30, |   |
|                       |                                            |   | 2010                                           |      |   | 2009 |   |
|                       |                                            |   |                                           | $’M |   |   |   | $’M |   |
| Foreign exchange contracts | Other (expense)/income, net                     |   |                                           | 38.5      |   |   |   | (14.2 | ) |

|                             |   | Carrying |   |   | Fair value |   |
|----------------------------------|--------|----------|--------|--------|------------|--------|
|                             |   | value    |   |   |       |   |   |   |   |   |   |   |   |   |   |
|                             |   |     |   |   | Total      |   |   | Level 1 |   |   | Level 2 |   |   | Level 3 |   |
|                             |   | $'M      |   |   | $'M        |   |   | $'M |   |   | $'M |   |   | $'M |   |
| Financial assets:                |   |     |   |   |       |   |   |   |   |   |   |   |   |   |   |
| Available-for-sale securities(1) |   |     | 70.6   |   |       |   | 70.6 |   |   |   | 70.6 |   |   |   | - |   |   |   | - |   |
| Foreign exchange contracts       |   |     | 2.3    |   |       |   | 2.3 |   |   |   | - |   |   |   | 2.3 |   |   |   | - |   |
|                             |   |     |   |   |       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Financial liabilities:           |   |     |   |   |       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign exchange contracts       |   |     | 5.8    |   |       |   | 5.8 |   |   |   | - |   |   |   | 5.8 |   |   |   | - |   |

----

|   | · | Available-for-sale securities – the fair values of available-for-sale securities are estimated based on quoted market prices for those investments. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Foreign exchange contracts – the fair values of the swap and forward foreign exchange contracts have been determined using an income approach based on current market expectations about the future cash flows. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          |   | June 30, 2010 |      |   | December 31, 2009 |   |
|-------------------------------|--------|---------------|-----------|--------|-------------------|--------|
|                          |   | Carrying      |      |   |              |   |   | Carrying |   |   |   |   |
|                          |   | amount        |      |   | Fair value        |   |   | amount |   |   | Fair value |   |
|                          |   |          | $’M |   |              |   | $’M |   |   |   | $’M |   |   |   | $’M |   |
|                          |   |          |      |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Financial liabilities:        |   |          |      |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Convertible bonds             |   |          | 1,100.0   |   |              |   | 1,067.6 |   |   |   | 1,100.0 |   |   |   | 1,067.0 |   |
| Building financing obligation |   |          | 7.3       |   |              |   | 8.4 |   |   |   | 46.7 |   |   |   | 47.3 |   |

|   | · | Convertible bonds – the fair value of Shire’s $1,100 million 2.75% convertible bonds due 2014 is estimated by reference to the market price of the instrument as the convertible bonds are publicly traded. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Building financing obligations - the fair value of building financing obligations are estimated based on the present value of future cash flows, and an estimate of the residual value of the underlying property at the end of the lease term, associated with these obligations. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                           |   | 3 months to |      |   | 3 months to |   |      | 6 months to |   |   | 6 months to |   |
|------------------------------------------------|--------|-------------|-----------|--------|-------------|--------|-----------|-------------|--------|--------|-------------|--------|
|                                           |   | June 30,    |      |   | June 30,    |   |      | June 30,    |   |   | June 30,    |   |
|                                           |   | 2010        |      |   | 2009        |   |      | 2010        |   |   | 2009        |   |
| Amounts attributable to Shire plc shareholders |   |        | $’M |   |        |   | $’M |        |   |   | $’M   |   |   |   | $’M |   |
| Numerator for basic earnings per share         |   |        | 160.5     |   |        |   | 44.1      |        |   |   | 326.2       |   |   |   | 257.7 |   |
| Interest on convertible bonds, net of tax (1)  |   |        | 8.4       |   |        |   | -         |        |   |   | 16.8        |   |   |   | - |   |
| Numerator for diluted earnings per share       |   |        | 168.9     |   |        |   | 44.1      |        |   |   | 343.0       |   |   |   | 257.7 |   |
|                                           |   |        |      |   |        |   |      |        |   |   |        |   |   |   |   |   |
|                                           |   |        |      |   |        |   |      |        |   |   |        |   |   |   |   |   |
| Weighted average number of shares:             |   |        |      |   |        |   |      |        |   |   |        |   |   |   |   |   |
|                                      |   | Millions    |      |   | Millions    |   |      | Millions    |   |   | Millions    |   |
| Basic(2)                                       |   |        | 546.6     |   |        |   | 539.9     |        |   |   | 545.7       |   |   |   | 539.7 |   |
| Effect of dilutive shares:                     |   |        |      |   |        |   |      |        |   |   |        |   |   |   |   |   |
| Stock based awards to employees(3)             |   |        | 10.2      |   |        |   | 3.5       |        |   |   | 10.2        |   |   |   | 5.3 |   |
| Convertible bonds 2.75% due 2014(4)            |   |        | 33.2      |   |        |   | -         |        |   |   | 33.2        |   |   |   | - |   |
| Diluted                                        |   |        | 590.0     |   |        |   | 543.4     |        |   |   | 589.1       |   |   |   | 545.0 |   |

| (1) | For the three and six month periods ended June 30, 2009 interest on the convertible bonds has not been added back as the effect would be anti-dilutive. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Excludes shares purchased by the ESOT and presented by the Company as treasury stock. |
|-----|---------------------------------------------------------------------------------------|

| (3) | Calculated using the treasury stock method. |
|-----|---------------------------------------------|

| (4) | Calculated using the “if-converted” method. |
|-----|---------------------------------------------------------|

|                             |   | 3 months to   |   |   | 3 months to       |   |   | 6 months to   |   |   | 6 months to       |   |
|----------------------------------|--------|---------------|--------|--------|-------------------|--------|--------|---------------|--------|--------|-------------------|--------|
|                             |   | June 30,      |   |   | June 30,          |   |   | June 30,      |   |   | June 30,          |   |
|                             |   | 2010 (1) |   |   | 2009 (1) (2) |   |   | 2010 (1) |   |   | 2009 (1) (2) |   |
|                             |   | No. of shares |   |   | No. of shares     |   |   | No. of shares |   |   | No. of shares     |   |
|                             |   | Millions      |   |   | Millions          |   |   | Millions      |   |   | Millions          |   |
| Share options out of the money   |   |          | 8.1    |   |              |   | 31.3   |          |   |   | 8.1               |   |   |   | 18.9 |   |
| Convertible bonds 2.75% due 2014 |   |          | -      |   |              |   | 32.7   |          |   |   | -                 |   |   |   | 32.7 |   |

| (1) | In the three and six months to June 30, 2010 and 2009 certain stock options have been excluded from the calculation of the diluted weighted average number of shares because their exercise prices exceeded Shire plc’s average share price during the calculation period. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | In the three and six months to June 30, 2009 the ordinary shares underlying the convertible bonds have not been included in the calculation of the diluted weighted average number of shares, because the effect of their inclusion would be anti-dilutive. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                        |   | SP     |      |   | HGT    |   |      | All Other |   |   | Total     |   |
|---------------------------------------------|--------|--------|-----------|--------|--------|--------|-----------|-----------|--------|--------|-----------|--------|
| 3 months to June 30, 2010                   |   |   | $’M |   |   |   | $’M |      |   |   | $’M |   |   |   | $’M |   |
| Product sales                               |   |   | 551.3     |   |   |   | 213.0     |      |   |   | -         |   |   |   | 764.3 |   |
| Royalties                                   |   |   | 44.2      |   |   |   | -         |      |   |   | 38.5      |   |   |   | 82.7 |   |
| Other revenues                              |   |   | 0.5       |   |   |   | 0.6       |      |   |   | 1.3       |   |   |   | 2.4 |   |
| Total revenues                              |   |   | 596.0     |   |   |   | 213.6     |      |   |   | 39.8      |   |   |   | 849.4 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Cost of product sales(1)                    |   |   | 84.6      |   |   |   | 34.5      |      |   |   | -         |   |   |   | 119.1 |   |
| Research and development(1)                 |   |   | 84.8      |   |   |   | 62.2      |      |   |   | -         |   |   |   | 147.0 |   |
| Selling, general and administrative(1)      |   |   | 236.6     |   |   |   | 61.9      |      |   |   | 55.9      |   |   |   | 354.4 |   |
| Gain on sale of product rights              |   |   | (4.1      | )      |   |   | -         |      |   |   | -         |   |   |   | (4.1 | ) |
| Reorganization costs                        |   |   | 3.3       |   |   |   | -         |      |   |   | 5.3       |   |   |   | 8.6 |   |
| Total operating expenses                    |   |   | 405.2     |   |   |   | 158.6     |      |   |   | 61.2      |   |   |   | 625.0 |   |
| Operating income/(loss)                     |   |   | 190.8     |   |   |   | 55.0      |      |   |   | (21.4     | )      |   |   | 224.4 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Total assets                                |   |   | 2,081.5   |   |   |   | 1,574.3   |      |   |   | 1,213.1   |   |   |   | 4,868.9 |   |
| Long-lived assets(2)                        |   |   | 169.5     |   |   |   | 587.4     |      |   |   | 48.8      |   |   |   | 805.7 |   |
| Capital expenditure on long-lived assets(2) |   |   | 2.7       |   |   |   | 161.9     |      |   |   | 2.1       |   |   |   | 166.7 |   |

| (1) | Depreciation from manufacturing plants ($9.8 million) and amortization of favorable manufacturing contracts ($0.4 million) is included in Cost of product sales; depreciation of research and development assets ($3.5 million) is included in Research and development; and all other depreciation and amortization ($50.4 million) is included in Selling, general and administrative. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Long-lived assets comprise all non-current assets, excluding goodwill and other intangible assets, deferred tax assets, investments, income tax receivable and financial instruments. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                        |   | SP     |      |   | HGT    |   |      | All Other |   |   | Total     |   |
|---------------------------------------------|--------|--------|-----------|--------|--------|--------|-----------|-----------|--------|--------|-----------|--------|
| 3 months to June 30, 2009                   |   |   | $’M |   |   |   | $’M |      |   |   | $’M |   |   |   | $’M |   |
| Product sales                               |   |   | 427.2     |   |   |   | 131.2     |      |   |   | -         |   |   |   | 558.4 |   |
| Royalties                                   |   |   | 16.0      |   |   |   | -         |      |   |   | 50.9      |   |   |   | 66.9 |   |
| Other revenues                              |   |   | 1.1       |   |   |   | 0.4       |      |   |   | 2.9       |   |   |   | 4.4 |   |
| Total revenues                              |   |   | 444.3     |   |   |   | 131.6     |      |   |   | 53.8      |   |   |   | 629.7 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Cost of product sales(1)                    |   |   | 70.1      |   |   |   | 21.8      |      |   |   | 4.5       |   |   |   | 96.4 |   |
| Research and development(1)                 |   |   | 95.1      |   |   |   | 60.8      |      |   |   | 2.8       |   |   |   | 158.7 |   |
| Selling, general and administrative(1)      |   |   | 236.0     |   |   |   | 47.9      |      |   |   | 50.8      |   |   |   | 334.7 |   |
| Reorganization costs                        |   |   | 2.9       |   |   |   | -         |      |   |   | -         |   |   |   | 2.9 |   |
| Integration and acquisition costs           |   |   | 0.8       |   |   |   | 1.5       |      |   |   | -         |   |   |   | 2.3 |   |
| Total operating expenses                    |   |   | 404.9     |   |   |   | 132.0     |      |   |   | 58.1      |   |   |   | 595.0 |   |
| Operating income/(loss)                     |   |   | 39.4      |   |   |   | (0.4      | )         |   |   | (4.3      | )      |   |   | 34.7 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Total assets                                |   |   | 2,169.5   |   |   |   | 1,278.3   |      |   |   | 773.5     |   |   |   | 4,221.3 |   |
| Long-lived assets(2)                        |   |   | 211.0     |   |   |   | 331.0     |      |   |   | 60.1      |   |   |   | 602.1 |   |
| Capital expenditure on long-lived assets(2) |   |   | 14.0      |   |   |   | 43.2      |      |   |   | 2.7       |   |   |   | 59.9 |   |

| (1) | Depreciation from manufacturing plants ($7.9 million) and amortization of favorable manufacturing contracts ($0.4 million) is included in Cost of product sales; depreciation of research and development assets ($3.8 million) is included in Research and development; and all other depreciation and amortization ($50.2 million) is included in Selling, general and administrative. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred tax assets, investments, income tax receivable and financial instruments). |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                        |   | SP     |      |   | HGT    |   |      | All Other |   |   | Total     |   |
|---------------------------------------------|--------|--------|-----------|--------|--------|--------|-----------|-----------|--------|--------|-----------|--------|
| 6 months to June 30, 2010                   |   |   | $’M |   |   |   | $’M |      |   |   | $’M |   |   |   | $’M |   |
| Product sales                               |   |   | 1,092.6   |   |   |   | 389.8     |      |   |   | -         |   |   |   | 1,482.4 |   |
| Royalties                                   |   |   | 102.8     |   |   |   | -         |      |   |   | 75.2      |   |   |   | 178.0 |   |
| Other revenues                              |   |   | 1.2       |   |   |   | 1.3       |      |   |   | 2.6       |   |   |   | 5.1 |   |
| Total revenues                              |   |   | 1,196.6   |   |   |   | 391.1     |      |   |   | 77.8      |   |   |   | 1,665.5 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Cost of product sales(1)                    |   |   | 165.0     |   |   |   | 56.0      |      |   |   | -         |   |   |   | 221.0 |   |
| Research and development(1)                 |   |   | 158.7     |   |   |   | 119.3     |      |   |   | -         |   |   |   | 278.0 |   |
| Selling, general and administrative(1)      |   |   | 486.1     |   |   |   | 124.7     |      |   |   | 103.5     |   |   |   | 714.3 |   |
| Gain on sale of product rights              |   |   | (4.1      | )      |   |   | -         |      |   |   | -         |   |   |   | (4.1 | ) |
| Reorganization costs                        |   |   | 6.7       |   |   |   | -         |      |   |   | 6.9       |   |   |   | 13.6 |   |
| Integration and acquisition costs           |   |   | 0.6       |   |   |   | -         |      |   |   | -         |   |   |   | 0.6 |   |
| Total operating expenses                    |   |   | 813.0     |   |   |   | 300.0     |      |   |   | 110.4     |   |   |   | 1,223.4 |   |
| Operating income/(loss)                     |   |   | 383.6     |   |   |   | 91.1      |      |   |   | (32.6     | )      |   |   | 442.1 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Total assets                                |   |   | 2,081.5   |   |   |   | 1,574.3   |      |   |   | 1,213.1   |   |   |   | 4,868.9 |   |
| Long-lived assets(2)                        |   |   | 169.5     |   |   |   | 587.4     |      |   |   | 48.8      |   |   |   | 805.7 |   |
| Capital expenditure on long-lived assets(2) |   |   | 5.0       |   |   |   | 187.4     |      |   |   | 4.0       |   |   |   | 196.4 |   |

| (1) | Depreciation from manufacturing plants ($18.4 million) and amortization of favorable manufacturing contracts ($0.9 million) is included in Cost of product sales; depreciation of research and development assets ($7.2 million) is included in Research and development; and all other depreciation and amortization ($101.3 million) is included in Selling, general and administrative. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Long-lived assets comprise all non-current assets, excluding goodwill and other intangible assets, deferred tax assets, investments, income tax receivable and financial instruments. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                        |   | SP     |      |   | HGT    |   |      | All Other |   |   | Total     |   |
|---------------------------------------------|--------|--------|-----------|--------|--------|--------|-----------|-----------|--------|--------|-----------|--------|
| 6 months to June 30, 2009                   |   |   | $’M |   |   |   | $’M |      |   |   | $’M |   |   |   | $’M |   |
| Product sales                               |   |   | 1,059.7   |   |   |   | 254.6     |      |   |   | -         |   |   |   | 1,314.3 |   |
| Royalties                                   |   |   | 16.9      |   |   |   | -         |      |   |   | 100.6     |   |   |   | 117.5 |   |
| Other revenues                              |   |   | 8.1       |   |   |   | 1.8       |      |   |   | 5.7       |   |   |   | 15.6 |   |
| Total revenues                              |   |   | 1,084.7   |   |   |   | 256.4     |      |   |   | 106.3     |   |   |   | 1,447.4 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Cost of product sales(1)                    |   |   | 131.3     |   |   |   | 41.7      |      |   |   | 7.0       |   |   |   | 180.0 |   |
| Research and development(1)                 |   |   | 221.7     |   |   |   | 117.6     |      |   |   | 5.3       |   |   |   | 344.6 |   |
| Selling, general and administrative(1)      |   |   | 465.8     |   |   |   | 93.9      |      |   |   | 93.6      |   |   |   | 653.3 |   |
| Reorganization costs                        |   |   | 5.1       |   |   |   | -         |      |   |   | -         |   |   |   | 5.1 |   |
| Integration and acquisition costs           |   |   | 1.5       |   |   |   | 2.3       |      |   |   | -         |   |   |   | 3.8 |   |
| Total operating expenses                    |   |   | 825.4     |   |   |   | 255.5     |      |   |   | 105.9     |   |   |   | 1,186.8 |   |
| Operating income                            |   |   | 259.3     |   |   |   | 0.9       |      |   |   | 0.4       |   |   |   | 260.6 |   |
|                                        |   |   |      |   |   |   |      |      |   |   |      |   |   |   |   |   |
| Total assets                                |   |   | 2,169.5   |   |   |   | 1,278.3   |      |   |   | 773.5     |   |   |   | 4,221.3 |   |
| Long-lived assets(2)                        |   |   | 211.0     |   |   |   | 331.0     |      |   |   | 60.1      |   |   |   | 602.1 |   |
| Capital expenditure on long-lived assets(2) |   |   | 21.0      |   |   |   | 82.7      |      |   |   | 6.7       |   |   |   | 110.4 |   |

| (1) | Depreciation from manufacturing plants ($11.5 million) and amortization of favorable manufacturing contracts ($0.9 million) is included in Cost of product sales; depreciation of research and development assets ($7.8 million) is included in Research and development; and all other depreciation and amortization ($97.5 million) is included in Selling, general and administrative. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred tax assets, investments, income tax receivable and financial instruments). |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

|   | · | On May 4, 2010 the FDA approved a change to the prescribing information for the once-daily ADHD treatment VYVANSE, to include supplemental data demonstrating significant improvement in attention in adults with ADHD across all six assessments conducted at two, four, eight, 10, 12 and 14 hours after administration as measured by average Permanent Product Measure of Performance total scores, as well as at each time point measured.  VYVANSE is now the first and only oral ADHD long-acting stimulant treatment to have efficacy data at 14 hours post-dose for adult patients included in its product labeling. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On July 5, 2010 ANVISA, the Brazilian health authority, granted approval of the  Marketing Authorization Application (“MAA”) for the product under the trade name VENVANSE for the treatment of ADHD in children aged 6 to 12. This represents the first approval of lisdexamfetamine dimesylate in Latin America. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On July 8, 2010 Shire announced that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the US District Court for the District of Delaware against Zydus for the infringement of the US Patent No. 6,773,720, (the “’720 patent”). The lawsuit was filed as a result of an ANDA filed by Zydus seeking FDA approval to market and sell generic versions of LIALDA prior to the expiration of the ’720 patent. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On July 6, 2010 Shire announced the FDA approval of DAYTRANA for the treatment of ADHD in adolescents aged 13 to 17 years. DAYTRANA, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children aged 6 to 12 years. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ·   | REPLAGAL is experiencing significant demand globally and is now the market leader in many key regions, due principally to a competitor’s ongoing supply disruption. Currently there are approximately 2,000 patients worldwide being treated with REPLAGAL and Shire has capacity to add 150-250 more patients in 2010. Shire anticipates that it could add 250-350 more patients phased throughout 2011. Shire’s continuing priority is to ensure the long term, uninterrupted supply to patients currently being treated with REPLAGAL and we will continue to monitor demand and manage supply carefully. |
|--------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ·   | On August 3, Shire withdrew the BLA for REPLAGAL in order to consider updating the submission with additional clinical data. |
|--------|--------------------|------------------------------------------------------------------------------------------------------------------------------|

|   | ·   | On June 25, 2010 Shire received a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) on the marketing authorization for VPRIV, its enzyme replacement therapy (“ERT”) for the Treatment of Type 1 Gaucher Disease in the EU. The CHMP positive opinion will now be forwarded to the European Commission for ratification. In addition to the CHMP positive opinion, VPRIV has received orphan drug designation from the Committee for Orphan Medicinal Products. In many European countries patients have been receiving VPRIV on an early access basis, developed in partnership with national and regional authorities. |
|--------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ·   | With the accelerated adoption of VPRIV worldwide, and the earlier than anticipated US approval and EU positive opinion, Shire expects continued high demand, and currently has about 850 patients on therapy with capacity to support approximately 1,000 patients in 2010. As a result, Shire is now implementing a program with physicians and patients to monitor demand and manage requests from new patients carefully in order to ensure long-term, uninterrupted treatment with VPRIV. |
|--------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | A supplemental New Drug Application (“sNDA”) was submitted to the FDA on April 28, 2010 to seek approval for INTUNIV as adjunctive treatment with long-acting oral stimulants for the treatment of ADHD in children and adolescents.  |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In the six months to June 30, 2010 Shire was notified that three separate ANDA were submitted under the Hatch-Waxman Act seeking permission to market generic versions of 1mg, 2mg, 3mg, and 4mg strengths of INTUNIV. The notices were from Teva, Actavis and Anchen. Within the requisite period of 45 days, Shire filed lawsuits in the US District Court of the District of Delaware against each of Teva, Actavis and Anchen for infringement of certain of Shire’s INTUNIV patents. The filing of the lawsuits triggered a stay of approval of these ANDAs for up to 30 months.  No trial date has been set. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | HGT-1410 is in development as an ERT for the treatment of Sanfilippo Syndrome, a lysosomal storage disorder. The product has been granted orphan drug designation in the US and in the EU. The Company initiated a Phase 1/2 clinical trial in August 2010. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | SPD 547 is in early stage development for the treatment of ADHD. A feasibility study in humans using microdosing has been completed and results indicate characteristics suitable for entering formal Phase 1 trials. The Phase 1 program is expected to be initiated in the third quarter of 2010 with results throughout 2011. GCW could potentially improve on the current guanfacine profile to minimize known food, GI and sedation effects. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ·   | On August 3, 2010 Shire announced that it was launching a voluntary public takeover offer for all the shares in Movetis, the Belgium-based European specialty GI company, for a fully diluted equity purchase price of €428 million. Movetis’ board unanimously supports the transaction and Institutional shareholders holding 38.9% of Movetis’ shares have unconditionally agreed to accept the offer. It is anticipated that the takeover offer, which is contingent upon the fulfilment of certain conditions, will open for acceptance in September. |
|--------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On June 30, 2010 Shire purchased Lexington Technology Park in Lexington, Massachusetts for a cash purchase price of $165 million. The purchase underlines our investment in the growth of Shire’s HGT business, and gives Shire the ownership of an additional 570,000 square feet of expansion potential available under the current permit, including 170,000 square feet already under construction. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | · | Product sales were up 37% to $764 million (2009: $558 million) with growth from both products excluding ADDERALL XR (“Core Products”) (up 39% to $684 million) and product sales from ADDERALL XR (up 19% to $80 million). On a Non-GAAP CER basis, Core Product sales were up 42%. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | The continued growth in Core Product sales was the result of strong performance across the portfolio: |
|--------|--------|-------------------------------------------------------------------------------------------------------|

|   | · | VYVANSE (up 30% to $148 million, Non-GAAP CER: up 29%); |
|--------|--------|---------------------------------------------------------|

|   | · | ELAPRASE (up 17% to $100 million, Non-GAAP CER: up 20%); |
|--------|--------|----------------------------------------------------------|

|   | · | REPLAGAL (up 84% to $82 million, Non-GAAP CER: up 93%); |
|--------|--------|---------------------------------------------------------|

|   | · | LIALDA/MEZAVANT (up 27% to $70 million, Non-GAAP CER: up 27%); and |
|--------|--------|-------------------------------------------------------------------------|

|   | · | Recently launched INTUNIV ($51 million) and VPRIV ($29 million). |
|--------|--------|----------------------------------------------------------------------------|

|   | · | Total revenues were up 35% (Non-GAAP CER: up 37%) to $849 million (2009: $630 million), as a result of increased product sales and higher royalties (up 24% due to higher royalty income on sales of authorized generic ADDERALL XR). |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Operating income increased by $189 million, or 547%, to $224 million (2009: $35 million). Operating income in the second quarter of 2009 included costs of $37 million on amendment of an INTUNIV license. Excluding this item, operating income increased by $152 million in 2010 due to higher total revenues and improved total operating expense ratios compared to 2009, despite increased investment in R&D programs and selling, general and administrative (“SG&A”) costs in support of recent growth. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|           |   | 3 months to |   |   | 3 months to |   |   |   |   |
|----------------|--------|-------------|--------|--------|-------------|--------|--------|--------|--------|
|           |   | June 30,    |   |   | June 30,    |   |   |   |   |
|           |   | 2010        |   |   | 2009        |   |   | change |   |
|           |   | $'M         |   |   | $'M         |   |   | %      |   |
| Product sales  |   |        | 764.3  |   |        |   | 558.4  |   |   |   | +37 |   |
| Royalties      |   |        | 82.7   |   |        |   | 66.9   |   |   |   | +24 |   |
| Other revenues |   |        | 2.4    |   |        |   | 4.4    |   |   |   | -45 |   |
| Total          |   |        | 849.4  |   |        |   | 629.7  |   |   |   | +35 |   |

----

|                      |   | 3 months to |   |   | 3 months to |   |   |          |   |   |         |   |   |            |   |   |        |   |
|---------------------------|--------|-------------|--------|--------|-------------|--------|--------|---------------|--------|--------|--------------|--------|--------|-----------------|--------|--------|-------------|--------|
|                      |   | June 30,    |   |   | June 30,    |   |   | Product sales |   |   | Non-GAAP CER |   |   | US prescription |   |   | Exit market |   |
|                      |   | 2010        |   |   | 2009        |   |   | growth        |   |   | growth       |   |   | growth1         |   |   | Share1      |   |
|                      |   | $'M         |   |   | $'M         |   |   | %             |   |   | %            |   |   | %               |   |   | %           |   |
| Specialty Pharmaceuticals |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |
| ADHD                      |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |
| VYVANSE                   |   |        | 148.0  |   |        |   | 114.2  |          |   |   | +30          |   |   |            | +29    |   |        |   | +29 |   |   |   | 14 |   |
| ADDERALL XR               |   |        | 80.4   |   |        |   | 67.4   |          |   |   | +19          |   |   |            | +18    |   |        |   | -24 |   |   |   | 8 |   |
| INTUNIV                   |   |        | 51.2   |   |        |   | -      |          |   |   | n/a          |   |   |            | n/a    |   |        |   | n/a |   |   |   | 2 |   |
| DAYTRANA                  |   |        | 16.3   |   |        |   | 14.9   |          |   |   | +9           |   |   |            | +9     |   |        |   | -10 |   |   |   | 1 |   |
| EQUASYM                   |   |        | 8.2    |   |        |   | 4.9    |          |   |   | +67          |   |   |            | +77    |   |        |   | n/a |   |   |   | n/a | 2  |
|                      |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| GI                        |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| LIALDA / MEZAVANT         |   |        | 69.6   |   |        |   | 54.6   |          |   |   | +27          |   |   |            | +27    |   |        |   | +19 |   |   |   | 19 |   |
| PENTASA                   |   |        | 60.6   |   |        |   | 54.0   |          |   |   | +12          |   |   |            | +12    |   |        |   | -5 |   |   |   | 15 |   |
|                      |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| General Products          |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| FOSRENOL                  |   |        | 45.1   |   |        |   | 49.6   |          |   |   | -9           |   |   |            | -7     |   |        |   | -15 |   |   |   | 7 |   |
| CALCICHEW                 |   |        | 10.4   |   |        |   | 10.8   |          |   |   | -4           |   |   |            | +1     |   |        |   | n/a |   |   |   | n/a | 2  |
| CARBATROL                 |   |        | 23.0   |   |        |   | 20.8   |          |   |   | +11          |   |   |            | +11    |   |        |   | -7 |   |   |   | 14 |   |
| REMINYL/REMINYL XL        |   |        | 11.5   |   |        |   | 10.9   |          |   |   | +6           |   |   |            | +9     |   |        |   | n/a |   |   |   | n/a | 2  |
| XAGRID                    |   |        | 21.6   |   |        |   | 20.7   |          |   |   | +4           |   |   |            | +11    |   |        |   | n/a |   |   |   | n/a | 2  |
| Other product sales       |   |        | 5.4    |   |        |   | 4.4    |          |   |   | +23          |   |   |            | +19    |   |        |   | n/a |   |   |   | n/a |   |
|                      |   |        | 551.3  |   |        |   | 427.2  |          |   |   | +29          |   |   |            |   |   |        |   |   |   |   |   |   |   |
|                      |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |
| Human Genetic Therapies   |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |   |   |   |
| ELAPRASE                  |   |        | 99.8   |   |        |   | 85.3   |          |   |   | +17          |   |   |            | +20    |   |        |   | n/a | 2 |   |   | n/a |   |
| REPLAGAL                  |   |        | 81.9   |   |        |   | 44.4   |          |   |   | +84          |   |   |            | +93    |   |        |   | n/a | 3  |   |   | n/a | 3  |
| VPRIV                     |   |        | 28.7   |   |        |   | -      |          |   |   | n/a          |   |   |            | n/a    |   |        |   | n/a |   |   |   | n/a | 2  |
| FIRAZYR                   |   |        | 2.6    |   |        |   | 1.5    |          |   |   | +73          |   |   |            | +86    |   |        |   | n/a | 3  |   |   | n/a | 3  |
|                      |   |        | 213.0  |   |        |   | 131.2  |          |   |   | +62          |   |   |            |   |   |        |   |   |   |   |   |   |   |
| Total product sales       |   |        | 764.3  |   |        |   | 558.4  |          |   |   | +37          |   |   |            |   |   |        |   |   |   |   |   |   |   |
|                      |   |        |   |   |        |   |   |          |   |   |         |   |   |            |   |   |        |   |   |   |   |

| (1) | Data provided by IMS Health National Prescription Audit (“IMS NPA”). Exit market share represents the US market share in the week ending June 25, 2010. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | IMS NPA Data not available. |
|-----|-----------------------------|

| (3) | Not sold in the US in the second quarter of 2010. |
|-----|---------------------------------------------------|

----

----

|           |   | 3 months to |   |   | 3 months to |   |   |   |   |
|----------------|--------|-------------|--------|--------|-------------|--------|--------|--------|--------|
|           |   | June 30,    |   |   | June 30,    |   |   |   |   |
|           |   | 2010        |   |   | 2009        |   |   | Change |   |
|           |   | $'M         |   |   | $'M         |   |   | %      |   |
| 3TC and ZEFFIX |   |        | 38.1   |   |        |   | 39.4   |   |   |   | -3 |   |
| ADDERALL XR    |   |        | 27.5   |   |        |   | 13.6   |   |   |   | +102 |   |
| Others         |   |        | 17.1   |   |        |   | 13.9   |   |   |   | +23 |   |
| Total          |   |        | 82.7   |   |        |   | 66.9   |   |   |   | +24 |   |

----

----

|           |   | 6 months to |    |   | 6 months to |   |    |   |   |
|----------------|--------|-------------|---------|--------|-------------|--------|---------|--------|--------|
|           |   | June 30,    |    |   | June 30,    |   |    |   |   |
|           |   | 2010        |    |   | 2009        |   |    | change |   |
|           |   | $'M         |    |   | $'M         |   |    | %      |   |
| Product sales  |   |        | 1,482.4 |   |        |   | 1,314.3 |   |   |   | +13 |   |
| Royalties      |   |        | 178.0   |   |        |   | 117.5   |   |   |   | +51 |   |
| Other revenues |   |        | 5.1     |   |        |   | 15.6    |   |   |   | -67 |   |
| Total          |   |        | 1,665.5 |   |        |   | 1,447.4 |   |   |   | +15 |   |

----

|                      |   | 6 months toJune 30, |    |   | 6 months toJune 30, |   |    | Product sales |   |   | Non-GAAPCER |   |   | USprescription |   |   | Exit market |   |
|---------------------------|--------|---------------------|---------|--------|---------------------|--------|---------|---------------|--------|--------|-------------|--------|--------|----------------|--------|--------|-------------|--------|
|                      |   | 2010                |    |   | 2009                |   |    | growth        |   |   | growth      |   |   | growth1        |   |   | Share1      |   |
|                      |   | $'M                 |    |   | $'M                 |   |    | %             |   |   | %           |   |   | %              |   |   | %           |   |
| Specialty Pharmaceuticals |   |                |    |   |                |   |    |          |   |   |        |   |   |           |   |   |        |   |
| ADHD                      |   |                |    |   |                |   |    |          |   |   |        |   |   |           |   |   |        |   |
| VYVANSE                   |   |                | 302.4   |   |                |   | 230.7   |          |   |   | +31         |   |   |           | +31    |   |        |   | +31 |   |   |   | 14 |   |
| ADDERALL XR               |   |                | 172.2   |   |                |   | 363.3   |          |   |   | -53         |   |   |           | -53    |   |        |   | -48 |   |   |   | 8 |   |
| INTUNIV                   |   |                | 85.7    |   |                |   | -       |          |   |   | n/a         |   |   |           | n/a    |   |        |   | n/a |   |   |   | 2 |   |
| DAYTRANA                  |   |                | 34.7    |   |                |   | 34.8    |          |   | <-1 |        |   |   | -              |   |   |        | -11    |   |   |   | 1 |   |
| EQUASYM                   |   |                | 10.6    |   |                |   | 4.9     |          |   |   | +116        |   |   |           | +123   |   |        |   | n/a |   |   |   | n/a | 2  |
|                      |   |                |    |   |                |   |    |          |   |   |        |   |   |           |   |   |        |   |   |   |   |   |   |   |
| GI                        |   |                |    |   |                |   |    |          |   |   |        |   |   |           |   |   |        |   |   |   |   |   |   |   |
| LIALDA / MEZAVANT         |   |                | 133.2   |   |                |   | 104.0   |          |   |   | +28         |   |   |           | +28    |   |        |   | +21 |   |   |   | 19 |   |
| PENTASA                   |   |                | 118.8   |   |                |   | 105.2   |          |   |   | +13         |   |   |           | +13    |   |        |   | -5 |   |   |   | 15 |   |
|                      |   |                |    |   |                |   |    |          |   |   |        |   |   |           |   |   |        |   |   |   |   |   |   |   |
| General Products          |   |                |    |   |                |   |    |          |   |   |        |   |   |           |   |   |        |   |   |   |   |   |   |   |
| FOSRENOL                  |   |                | 92.1    |   |                |   | 89.5    |          |   |   | +3          |   |   |           | +2     |   |        |   | -14 |   |   |   | 7 |   |
| CALCICHEW                 |   |                | 19.8    |   |                |   | 20.4    |          |   |   | -3          |   |   |           | -4     |   |        |   | n/a |   |   |   | n/a | 2  |
| CARBATROL                 |   |                | 43.1    |   |                |   | 38.9    |          |   |   | +11         |   |   |           | +11    |   |        |   | -7 |   |   |   | 14 |   |
| REMINYL/REMINYL XL        |   |                | 23.9    |   |                |   | 18.3    |          |   |   | +31         |   |   |           | +28    |   |        |   | n/a |   |   |   | n/a | 2  |
| XAGRID                    |   |                | 45.0    |   |                |   | 40.8    |          |   |   | +10         |   |   |           | +10    |   |        |   | n/a |   |   |   | n/a | 2  |
| Other product sales       |   |                | 11.1    |   |                |   | 8.9     |          |   |   | +25         |   |   |           | +17    |   |        |   | n/a |   |   |   | n/a |   |
|                      |   |                | 1,092.6 |   |                |   | 1,059.7 |          |   |   | +3          |   |   |           |   |   |        |   |   |   |   |   |   |   |
|                      |   |                |    |   |                |   |    |          |   |   |        |   |   |           |   |   |        |   |   |   |   |   |   |   |
| Human Genetic Therapies   |   |                |    |   |                |   |    |          |   |   |        |   |   |           |   |   |        |   |   |   |   |   |   |   |
| ELAPRASE                  |   |                | 200.6   |   |                |   | 168.0   |          |   |   | +19         |   |   |           | +18    |   |        |   | n/a |   |   |   | n/a | 2  |
| REPLAGAL                  |   |                | 149.9   |   |                |   | 84.6    |          |   |   | +77         |   |   |           | +77    |   |        |   | n/a |   |   |   | n/a | 3  |
| VPRIV                     |   |                | 34.5    |   |                |   | -       |          |   |   | n/a         |   |   |           | n/a    |   |        |   | n/a |   |   |   | n/a | 2  |
| FIRAZYR                   |   |                | 4.8     |   |                |   | 2.0     |          |   |   | +140        |   |   |           | +143   |   |        |   | n/a |   |   |   | n/a | 3  |
|                      |   |                | 389.8   |   |                |   | 254.6   |          |   |   | +53         |   |   |           |   |   |        |   |   |   |   |   |   |   |
| Total product sales       |   |                | 1,482.4 |   |                |   | 1,314.3 |          |   |   | +13         |   |   |           |   |   |        |   |   |   |   |   |   |   |

| (1) | Data provided by IMS Health National Prescription Audit (“IMS NPA”). Exit market share represents the US market share in the week ending June 25, 2010. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | IMS NPA Data not available. |
|-----|-----------------------------|

| (3) | Not sold in the US in the first half of 2010. |
|-----|-----------------------------------------------|

----

----

|           |   | 6 months to |   |   | 6 months to |   |   |   |   |
|----------------|--------|-------------|--------|--------|-------------|--------|--------|--------|--------|
|           |   | June 30,    |   |   | June 30,    |   |   |   |   |
|           |   | 2010        |   |   | 2009        |   |   | Change |   |
|           |   | $'M         |   |   | $'M         |   |   | %      |   |
| 3TC and ZEFFIX |   |        | 74.7   |   |        |   | 78.3   |   |   |   | -5 |   |
| ADDERALL XR    |   |        | 68.3   |   |        |   | 13.6   |   |   |   | +402 |   |
| Others         |   |        | 35.0   |   |        |   | 25.6   |   |   |   | +37 |   |
| Total          |   |        | 178.0  |   |        |   | 117.5  |   |   |   | +51 |   |

----

----

----

|                          |   | June 30, |      |   | December 31, |   |
|-------------------------------|--------|----------|-----------|--------|--------------|--------|
|                          |   | 2010     |      |   | 2009         |   |
|                          |   |     | $’M |   |         |   | $’M |   |
| Cash and cash equivalents     |   |     | 682.5     |   |         |   | 498.9 |   |
| Convertible debt              |   |     | 1,100.0   |   |         |   | 1,100.0 |   |
| Building financing obligation |   |     | 7.3       |   |         |   | 46.7 |   |
| Total debt                    |   |     | 1,107.3   |   |         |   | 1,146.7 |   |
| Net debt                      |   |     | (424.8    | )      |         |   | (647.8 | ) |

----

----

----

| 2.01   | Agreement and Plan of Merger by and among Shire Pharmaceuticals Group plc, Transkaryotic Therapies, Inc. and Sparta Acquisition Corporation, dated as of April 21, 2005.(1)                                                                                                                                                                                                                                                                   |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 2.02   | Agreement of Merger dated as of February 20, 2007 among Shire plc, Shuttle Corporation and New River Pharmaceuticals, Inc.(2)                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 2.03   | Business Combination Agreement dated as of July 3, 2008 between Maia Elfte Vermögensverwaltungs GmbH and Jerini AG. (3)                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 3.01   | Form of Memorandum of Association of Shire plc as adopted by a special resolution passed on April 10, 2008 and amended by a special resolution passed on September 24, 2008 and the form of Articles of Association of Shire plc as adopted by a special resolution passed on May 8, 2008 and amended by a special resolution passed on September 24, 2008. (4)                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 4.01   | Form of Assignment and Novation Agreement between Shire Limited, Shire plc, JPMorgan Chase Bank, N.A. dated April 16, 2008 relating to the Deposit Agreement among Shire plc, JPMorgan Chase Bank, N.A. as depositary and all holders from time to time of ADRs issued thereunder dated November 21, 2005.(5)                                                                                                                            |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 4.02   | Form of Deposit Agreement among Shire plc, JPMorgan Chase Bank, N.A. as depositary and all holders from time to time of ADRs issued thereunder dated November 21, 2005. (6)                                                                                                                                                                                                                                                                   |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 4.03   | Form of Ordinary Share Certificate of Shire Limited. (7)                                                                                                                                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 4.04   | Form of American Depositary Receipt Certificate of Shire Limited. (8)                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 4.05   | Trust Deed for the New Shire Income Access Trust, dated August 29, 2008. (9)                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.01  | Tender and Support Agreement dated as of February 20, 2007 among Shire plc, Mr. Randal J. Kirk and the other parties namedtherein. (10)                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.02  | Multicurrency Term and Revolving Facilities Agreement as of February 20, 2007 by and among Shire plc, ABN AMRO Bank N.V., Barclays Capital, Citigroup Global Markets Limited, The Royal Bank of Scotland plc, and Barclays Bank plc. (11)                                                                                                                                                                                                     |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.03  | Accession and Amendment Deed dated April 15, 2008 between Shire Limited, Shire plc, certain subsidiaries of Shire plc and Barclays Bank PLC as Facility Agent relating to a US $1,200,000,000 facility agreement dated February 20, 2007 (as amended by a syndication and amendment agreement dated July 19, 2007). (12)                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.04  | Subscription Agreement dated May 2, 2007 relating to the 2.75% Convertible Bonds due 2014 between Shire plc and ABN AMRO Bank N.V. and NM Rothschild & Sons Limited (trading together as ABN AMRO Rothschild, an unincorporated equity capital markets joint venture) and Barclays Bank PLC and Citigroup Global Markets Limited and Goldman Sachs International and Morgan Stanley & Co. International plc and others. (13)          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.05  | Amending Subscription Agreement dated May 8, 2007 relating to the 2.75% Convertible Bonds due 2014 between Shire plc and ABN AMRO Bank N.V. and NM Rothschild & Sons Limited (trading together as ABN AMRO Rothschild, an unincorporated equity capital markets joint venture) and Barclays Bank PLC and Citigroup Global Markets Limited and Goldman Sachs International and Morgan Stanley & Co. International plc and others. (14) |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.06  | Trust Deed dated May 9, 2007 relating to the 2.75% Convertible Bonds due 2014 between Shire plc and BNY Corporate Trustee Services Limited. (15)                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.07  | Supplemental Trust Deed dated April 15, 2008 between Shire Limited, Shire plc and BNY Corporate Trustee Services Limited relating to a trust deed dated May 9, 2007 relating to US $1,100,000,000 2.75% Convertible Bonds due 2014. (16)                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.08  | Accession and Amendment Agreement dated April 15, 2008 between Shire Limited, Shire plc, BNY Corporate Trustee Services Limited and The Bank of New York relating to a paying and conversion agency agreement dated May 9, 2007 relating to US $1,100,000,000 2.75% Convertible Bonds due 2014. (17)                                                                                                                                          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.09* | Revised and Restated Master License Agreement dated November 20, 1995 among Shire BioChem Inc (f/k/a BioChem Pharma Inc.), Glaxo Group Limited, Glaxo Wellcome Inc. (formerly Glaxo Canada Inc.), Glaxo                                                                                                                                                                                                                                       |

----

|   | Wellcome Inc. (formerly Glaxo Inc.), Tanaud Holdings (Barbados) Limited, Tanaud International B.V. and Tanaud LLC. (18)                                                                     |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                        |
| 10.10* | Settlement Agreement, dated August 14, 2006 by and between Shire Laboratories Inc. and Barr Laboratories, Inc. (19)                                                                         |
|   |                                                                                                                                                                                        |
| 10.11* | Product Development and License Agreement, dated August 14, 2006 by and between Shire LLC and Duramed Pharmaceuticals, Inc. (20)                                                            |
|   |                                                                                                                                                                                        |
| 10.12* | Product Acquisition and License Agreement, dated August 14, 2006 by and among Shire LLC, Shire plc and Duramed Pharmaceuticals, Inc. (21)                                                   |
|   |                                                                                                                                                                                        |
| 10.13  | Service Agreement between Shire plc and Mr Angus Russell, dated March 10, 2004. (22)                                                                                                        |
|   |                                                                                                                                                                                        |
| 10.14  | Novation Agreement dated November 21, 2005 relating to the Employment Agreement of Angus Russell dated March 10, 2004. (23)                                                                 |
|   |                                                                                                                                                                                        |
| 10.15  | Novation Agreement dated April 11, 2008 relating to the Employment Agreement of Angus Russell dated March 10, 2004, as previously novated on November 21, 2005. (24)                        |
|   |                                                                                                                                                                                        |
| 10.16  | Form of Amended and Restated Employment Agreement between Shire plc and Mr Matthew Emmens, dated March 12, 2004. (25)                                                                       |
|   |                                                                                                                                                                                        |
| 10.17  | Amendment Agreement dated November 21, 2005 relating to the Amended and Restated Employment Agreement of Matthew Emmens dated March 12, 2004. (26)                                          |
|   |                                                                                                                                                                                        |
| 10.18  | Ratification and Guaranty dated November 21, 2005 relating to the Amended and Restated Employment Agreement of Matthew Emmens dated March 12, 2004. (27)                                    |
|   |                                                                                                                                                                                        |
| 10.19  | Amendment Agreement dated May 20, 2008 relating to the Amended and Restated Employment Agreement of Matthew Emmens dated March 12, 2004, as amended on November 21, 2005. (28)              |
|   |                                                                                                                                                                                        |
| 10.20  | Ratification and Guaranty dated May 20, 2008 relating to the Amended and Restated Employment Agreement of Matthew Emmens dated March 12, 2004. (29)                                         |
|   |                                                                                                                                                                                        |
| 10.21  | Form of Indemnity Agreement for Directors of Shire Limited. (30)                                                                                                                            |
|   |                                                                                                                                                                                        |
| 10.22  | Service Agreement between Shire Limited and Mr Angus Russell, dated July 2, 2008. (31)                                                                                                      |
|   |                                                                                                                                                                                        |
| 10.23  | Service Agreement between Shire Limited and Mr Graham Hetherington, dated July 2, 2008. (32)                                                                                                |
|   |                                                                                                                                                                                        |
| 10.24  | Form of Settlement Agreement and Mutual Release in re: Transkaryotic Therapies, Inc., by and between Shire Human Genetic Therapies, Inc., Shire plc and the parties set forth therein. (33) |
|   |                                                                                                                                                                                        |
| 10.25  | Amended Agreement dated February 24, 2009 relating to the Product Development and License Agreement dated August 14, 2006. (34)                                                             |
|   |                                                                                                                                                                                        |
| 10.26  | Amendment of the Service Agreement of A.C Russell dated January 15, 2010. (35)                                                                                                              |
|   |                                                                                                                                                                                        |
| 10.27  | Amendment to the Shire Portfolio Share Plan as adopted by the Annual General meeting held on April 27, 2010. (36)                                                                           |
|   |                                                                                                                                                                                        |
| 21     | List of Subsidiaries. (37)                                                                                                                                                                  |
|   |                                                                                                                                                                                        |
| 31.1   | Certification of Angus Russell pursuant to Rule 13a – 14 under The Exchange Act.                                                                                                      |
|   |                                                                                                                                                                                        |
| 31.2   | Certification of Graham Hetherington pursuant to Rule 13a – 14 under The Exchange Act.                                                                                                |
|   |                                                                                                                                                                                        |
| 32.1   | Certification of Angus Russell and Graham Hetherington pursuant to Section 906 of the Sarbanes – Oxley Act of 2002.                                                                   |

| (1)             | Incorporated by reference to Exhibit 99.02 to Shire’s Form 8-K filed on April 25, 2005.    |
|-----------------|--------------------------------------------------------------------------------------------------|
|            |                                                                                             |
| (2)             | Incorporated by reference to Exhibit 2.1 to Shire’s Form 8-K filed on February 23, 2007.   |
|            |                                                                                             |
| (3)   |  Incorporated by reference to Exhibit 2.1 to Shire’s Form 8-K filed on July 10, 2008. |
|            |                                                                                             |
| (4)             | Incorporated by reference to Exhibit 99.02 to Shire’s Form 8-K filed on October 1, 2008.   |
|            |                                                                                             |
| (5)             | Incorporated by reference to Exhibit 4.01 to Shire’s Form 8-K filed on May 23, 2008.       |

----

| (6)         | Incorporated by reference to Exhibit 4.02 to Shire’s Form 8-K filed on May 23, 2008.        |
|-----------------------|---------------------------------------------------------------------------------------------------|
|                  |                                                                                              |
| (7)    | Incorporated by reference to Exhibit 4.03 to Shire’s Form 8-K filed on May 23, 2008.        |
|                  |                                                                                              |
| (8)    | Incorporated by reference to Exhibit 4.04 to Shire’s Form 8-K filed on May 23, 2008.        |
|                  |                                                                                              |
| (9)              | Incorporated by reference to Exhibit 4.05 to Shire’s Form 10-K filed on February 27, 2009.  |
|                  |                                                                                              |
| (10)             | Incorporated by reference to Exhibit 99.1 to Shire’s Form 8-K filed on February 23, 2007.   |
|                  |                                                                                              |
| (11)             | Incorporated by reference to Exhibit 10.2 to Shire’s Form 10-Q filed on May 1, 2007.        |
|                  |                                                                                              |
| (12)                  | Incorporated by reference to Exhibit 10.01 to Shire’s Form 8-K filed on May 23, 2008.       |
|                  |                                                                                              |
| (13)                  | Incorporated by reference to Exhibit 10.1 to Shire’s Form 10-Q filed on August 2, 2007.     |
|                  |                                                                                              |
| (14)                  | Incorporated by reference to Exhibit 10.2 to Shire’s Form 10-Q filed on August 2, 2007.     |
|                  |                                                                                              |
| (15)                  | Incorporated by reference to Exhibit 10.3 to Shire’s Form 10-Q filed on August 2, 2007.     |
|                  |                                                                                              |
| (16)                  | Incorporated by reference to Exhibit 10.02 to Shire’s Form 8-K filed on May 23, 2008.       |
|                  |                                                                                              |
| (17)                  | Incorporated by reference to Exhibit 10.03 to Shire’s Form 8-K filed on May 23, 2008.       |
|                  |                                                                                              |
| (18)                  | Incorporated by reference to Exhibit 10.09 to Shire’s Form 10-K/A filed on May 30, 2008.    |
|                  |                                                                                              |
| (19)                  | Incorporated by reference to Exhibit 10.1 to Shire’s Form 10-Q filed on November 7, 2006.   |
|                  |                                                                                              |
| (20)                  | Incorporated by reference to Exhibit 10.2 to Shire’s Form 10-Q filed on November 7, 2006.   |
|                  |                                                                                              |
| (21)                  | Incorporated by reference to Exhibit 10.3 to Shire’s Form 10-Q filed on November 7, 2006.   |
|                  |                                                                                              |
| (22)                  | Incorporated by reference to Exhibit 10.11 to Shire’s Form 10-K filed on March 12, 2004.    |
|                  |                                                                                              |
| (23)                  | Incorporated by reference to Exhibit 10.03 to Shire’s Form 8-K filed on November 25, 2005.  |
|                  |                                                                                              |
| (24)                  | Incorporated by reference to Exhibit 10.06 to Shire’s Form 8-K filed on May 23, 2008.       |
|                  |                                                                                              |
| (25)                  | Incorporated by reference to Exhibit 10.13 to Shire’s Form 10-K filed on March 12, 2004.    |
|                  |                                                                                              |
| (26)                  | Incorporated by reference to Exhibit 10.01 to Shire’s Form 8-K filed on November 25, 2005.  |
|                  |                                                                                              |
| (27)                  | Incorporated by reference to Exhibit 10.02 to Shire’s Form 8-K filed on November 25, 2005.  |
|                  |                                                                                              |
| (28)                  | Incorporated by reference to Exhibit 10.04 to Shire’s Form 8-K filed on May 23, 2008.       |
|                  |                                                                                              |
| (29)                  | Incorporated by reference to Exhibit 10.05 to Shire’s Form 8-K filed on May 23, 2008.       |
|                  |                                                                                              |
| (30)                  | Incorporated by reference to Exhibit 10.07 to Shire’s Form 8-K filed on May 23, 2008.       |
|                  |                                                                                              |
| (31)                  | Incorporated by reference to Exhibit 10.22 to Shire’s Form 10-Q filed on November 10, 2008. |
|                  |                                                                                              |
| (32)                  | Incorporated by reference to Exhibit 10.23 to Shire’s Form 10-Q filed on November 10, 2008. |
|                  |                                                                                              |
| (33)                  | Incorporated by reference to Exhibit 10.24 to Shire’s Form 10-Q filed on November 10, 2008. |
|                  |                                                                                              |
| (34)                  | Incorporated by reference to Exhibit 10.25 to Shire’s Form 10-Q filed on May 7, 2009.       |
|                  |                                                                                              |
| (35)                  | Incorporated by reference to Exhibit 10.26 to Shire’s Form 10-K filed on February 26, 2010. |
|                  |                                                                                              |
| (36)                  | Incorporated by reference to Exhibit 10.27 to Shire’s Form 10-Q filed on May 6, 2010.       |
|                  |                                                                                              |
| (37)                  | Incorporated by reference to Exhibit 21 to Shire’s Form 10-K filed on February 27, 2009.    |

----

|           |   |                                 |   |
|----------------|--------|--------------------------------------|--------|
| Date:          | By:    | /s/ Angus Russell                    |   |
|           |   |                                 |   |
| August 9, 2010 |   | Angus RussellChief Executive Officer |   |
|           |   |                                 |   |

|           |   |                                       |   |
|----------------|--------|--------------------------------------------|--------|
| Date:          | By:    | /s/ Graham Hetherington                    |   |
|           |   |                                       |   |
| August 9, 2010 |   | Graham HetheringtonChief Financial Officer |   |
|           |   |                                       |   |
|           |   |                                       |   |

----